These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1835221)

  • 1. Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer.
    Goldspiel BR; Kohler DR
    DICP; 1991; 25(7-8):796-804. PubMed ID: 1835221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW; Uitterlinden P; de Jong FH
    Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
    Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
    Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
    Tyrrell CJ; Altwein JE; Klippel F; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP
    J Urol; 1991 Nov; 146(5):1321-6. PubMed ID: 1834864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
    Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
    J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    Schulze H; Senge T
    J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
    Chodak GW
    Urology; 1989 May; 33(5 Suppl):42-4. PubMed ID: 2523610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
    Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma.
    Murphy GP; Greco JM; Chin JL; Huben RP; Scott M; deHaan HA
    Urology; 1987 Feb; 29(2):185-90. PubMed ID: 2949417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer.
    Dijkman GA; del Moral PF; Plasman JW; Kums JJ; Delaere KP; Debruyne FM; Hutchinson FJ; Furr BJ
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):933-6. PubMed ID: 2149507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
    Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
    Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
    Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?
    Fernandez del Moral P; Litjens TT; Weil EH; Debruyne FM
    Urology; 1988 Aug; 32(2):137-40. PubMed ID: 2969641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of advanced carcinoma of the prostate with a depot luteinizing hormone-releasing hormone analogue (ICI-118630).
    Van Cangh PJ; Opsomer RJ
    J Urol; 1987 Jan; 137(1):61-4. PubMed ID: 2948026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
    Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
    J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
    Geldof AA; de Voogt HJ; Rao BR
    Prostate; 1987; 11(3):281-90. PubMed ID: 2960958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.